Login to Your Account

A Question of Class

Dapagliflozin FDA Rejection Not End of SGLT2 Inhibitors

By Trista Morrison

Monday, January 23, 2012

The FDA's decision to reject AstraZeneca plc and Bristol-Myers Squibb Co.'s Type II diabetes drug dapagliflozin last week was no surprise, given the drug's spotty safety record and a negative advisory panel vote. But the rejection isn't necessarily a death sentence for dapagliflozin, or for other SGLT2 inhibitors in development.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription